AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid.
TOP NEWS: AstraZeneca s, Daiichi s Enhertu receives US FDA approval lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment.
On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indicat